CN102846729A - 一种治疗胃溃疡的藏药 - Google Patents
一种治疗胃溃疡的藏药 Download PDFInfo
- Publication number
- CN102846729A CN102846729A CN2012103580122A CN201210358012A CN102846729A CN 102846729 A CN102846729 A CN 102846729A CN 2012103580122 A CN2012103580122 A CN 2012103580122A CN 201210358012 A CN201210358012 A CN 201210358012A CN 102846729 A CN102846729 A CN 102846729A
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- ulcer
- active component
- gastric ulcer
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 208000007107 Stomach Ulcer Diseases 0.000 title claims abstract description 31
- 201000005917 gastric ulcer Diseases 0.000 title claims abstract description 30
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims description 12
- 235000001892 vitamin D2 Nutrition 0.000 claims description 12
- 239000011653 vitamin D2 Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 abstract description 20
- 231100000397 ulcer Toxicity 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 11
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 208000007882 Gastritis Diseases 0.000 abstract description 6
- 201000006549 dyspepsia Diseases 0.000 abstract description 4
- 208000018556 stomach disease Diseases 0.000 abstract description 4
- 240000004980 Rheum officinale Species 0.000 abstract description 3
- 230000029087 digestion Effects 0.000 abstract description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 abstract description 2
- 208000036495 Gastritis atrophic Diseases 0.000 abstract description 2
- 206010017865 Gastritis erosive Diseases 0.000 abstract description 2
- 206010030216 Oesophagitis Diseases 0.000 abstract description 2
- 241001049107 Pterocephalus hookeri Species 0.000 abstract description 2
- 208000016644 chronic atrophic gastritis Diseases 0.000 abstract description 2
- 230000002183 duodenal effect Effects 0.000 abstract description 2
- 208000006881 esophagitis Diseases 0.000 abstract description 2
- 235000008081 Rheum officinale Nutrition 0.000 abstract 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052602 gypsum Inorganic materials 0.000 abstract 1
- 239000010440 gypsum Substances 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 238000002156 mixing Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 229960000905 indomethacin Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 210000001187 pylorus Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 208000011906 peptic ulcer disease Diseases 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 3
- 229960000620 ranitidine Drugs 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000880120 Ochotona erythrotis Species 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 241000123586 Dipsacaceae Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010052359 Gingival abscess Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000283965 Ochotona princeps Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241001625808 Trona Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000010448 nahcolite Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000004203 pyloric antrum Anatomy 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103580122A CN102846729B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗胃溃疡的藏药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012103580122A CN102846729B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗胃溃疡的藏药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102846729A true CN102846729A (zh) | 2013-01-02 |
CN102846729B CN102846729B (zh) | 2013-11-13 |
Family
ID=47393974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012103580122A Active CN102846729B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗胃溃疡的藏药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102846729B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105079344A (zh) * | 2015-09-09 | 2015-11-25 | 白玛仁增 | 一种治疗胃肠炎、胃溃疡、胆囊炎、黄疸性肝炎的复方藏药制剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102269751A (zh) * | 2011-04-25 | 2011-12-07 | 甘肃奇正藏药有限公司 | 六味能消制剂的检测方法 |
-
2012
- 2012-09-25 CN CN2012103580122A patent/CN102846729B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102269751A (zh) * | 2011-04-25 | 2011-12-07 | 甘肃奇正藏药有限公司 | 六味能消制剂的检测方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105079344A (zh) * | 2015-09-09 | 2015-11-25 | 白玛仁增 | 一种治疗胃肠炎、胃溃疡、胆囊炎、黄疸性肝炎的复方藏药制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN102846729B (zh) | 2013-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101129723A (zh) | 治疗便秘的一种中药制剂 | |
CN101019985B (zh) | 一种治疗便秘的中成药 | |
CN103182019A (zh) | 治疗复发性口腔溃疡的中药组合物 | |
CN101095856A (zh) | 一种治疗过敏性紫癜性肾炎的中药 | |
CN104940784A (zh) | 一种治疗慢性胃炎的中药组合物 | |
CN103933513B (zh) | 祛痘中药组合物 | |
CN102210818B (zh) | 治疗胃出血的中药 | |
CN102846728B (zh) | 一种治疗胃溃疡藏药的制备方法 | |
CN103751579A (zh) | 治疗鼻咽癌放疗引起口腔粘膜炎的药物组合物及其制备方法 | |
CN103055286B (zh) | 治疗慢性萎缩性胃炎的中药及其制备方法 | |
CN102846729B (zh) | 一种治疗胃溃疡的藏药 | |
CN103655931B (zh) | 治疗输尿管结石的中药组合物及其制备方法 | |
CN104997860A (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN101780220B (zh) | 一种治疗慢性胃炎的中药 | |
CN104800760A (zh) | 一种治疗肝胃郁热型反流性食管炎的中药组合物 | |
CN103908603B (zh) | 一种治疗痛风的中药组合物及其制备方法 | |
CN105726787A (zh) | 一种治疗溃疡性结肠炎的中药灌肠剂及其制备方法 | |
CN110151880A (zh) | 前列煎 | |
CN103948899A (zh) | 一种治疗萎缩性胃炎的藏药 | |
CN103736028A (zh) | 一种治疗口腔扁平苔藓的中药组合物 | |
CN103768451A (zh) | 治疗慢性胰腺炎的中药 | |
CN104027579A (zh) | 一种治疗口腔溃疡的中药制剂 | |
CN103520620B (zh) | 一种治疗脾胃虚弱型慢性胃炎的中药制剂及制备方法 | |
CN106110285B (zh) | 一种用于治疗上呼吸道及食管道疾病的中药组合物及其制剂和应用 | |
CN105726695A (zh) | 一种治疗慢性浅表性胃炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161101 Address after: 810000 Xining biological science and Technology Industrial Park, No. three, No. 18, Qinghai Patentee after: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Address before: 810003 Xining biological science and Technology Industrial Park, No. three, No. 18, Qinghai Patentee before: Jiumei Pengcuo |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Tibetan medicine for treating gastric ulcer Effective date of registration: 20200525 Granted publication date: 20131113 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2020630000001 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210517 Granted publication date: 20131113 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2020630000001 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Tibetan medicine for treating gastric ulcer Effective date of registration: 20210602 Granted publication date: 20131113 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2021630000003 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230608 Granted publication date: 20131113 Pledgee: Qinghai Chuangqi Finance Leasing Co.,Ltd. Pledgor: Jiumei Pengcuo|Qinghai Jiumei Zang Drug Drug Co.,Ltd. Registration number: Y2021630000003 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |